Pretargeted radioimmunotherapy in tumored mice using an in vivo 212Pb/212Bi generator

Antibody pretargeting system with Mab-streptavidin, clearing agent and DOTA-biotin provides the potential of 212Bi for solid tumor radiotherapy despite the release of 212Bi after 212Pb decay. Dosimetry calculations resulted in tumor dose at 93 rad/μCi and ratios of tumor to marrow and kidney at 386:1 and 12:1, respectively.